Title: Biologics in severe asthma: a state-of-the-art review

Authors: Bishal Gyawali, Steve N. Georas, and Sandhya Khurana

Summary:
Severe asthma presents a significant public health challenge, affecting millions globally with substantial morbidity and healthcare costs. Conventional treatments often fall short, leading to uncontrolled symptoms, frequent exacerbations, and reliance on systemic corticosteroids. The advent of biologic therapies has revolutionized the management paradigm for severe asthma, offering targeted approaches to address underlying inflammatory pathways. This review provides a comprehensive, state-of-the-art overview of biologics, summarizing evidence from key clinical trials, extension studies, and real-world data, along with insights into their efficacy, safety, and predictors of response.

Severe asthma is characterized by persistent symptoms despite high-dose inhaled corticosteroids and long-acting beta-agonists. Biologics are designed to target specific inflammatory mediators or cells implicated in asthma pathogenesis. Currently, available biologics primarily focus on Type 2 (T2) inflammation, driven by cytokines like interleukin-4 (IL-4), IL-5, and IL-13, and immunoglobulin E (IgE). These therapies include anti-IgE (omalizumab), anti-IL-5/5R (mepolizumab, reslizumab, benralizumab), and anti-IL-4RÎ± (dupilumab), each with distinct mechanisms of action that interfere with allergic or eosinophilic inflammatory cascades.

Clinical trials have consistently demonstrated the significant efficacy of biologics in Type 2 severe asthma. These therapies have been shown to substantially reduce the frequency of asthma exacerbations, improve lung function (FEV1), decrease daily reliance on oral corticosteroids, and enhance asthma control and quality of life. Landmark trials for each biologic have established their superiority over placebo in carefully selected patient populations, marking a pivotal shift in the therapeutic landscape for severe asthma.

Beyond clinical trials, real-world evidence and long-term extension studies further support the sustained effectiveness and safety of biologics in diverse patient cohorts. These studies confirm that the benefits observed in controlled settings translate to broader clinical practice, often showing even greater improvements due to optimized patient selection and adherence. Factors such as baseline eosinophil counts, fractional exhaled nitric oxide (FeNO), and prior exacerbation history often serve as predictors of a patient's likely response to specific biologic therapies.

The safety profiles of biologics for severe asthma are generally favorable, particularly when compared to the long-term adverse effects associated with systemic corticosteroids. While injection site reactions are common, serious adverse events are rare. Each biologic has a specific safety profile, including considerations for potential parasitic infections with omalizumab or hypereosinophilia with anti-IL-5 agents, which are carefully monitored. Overall, the benefit-risk ratio strongly favors biologic use in appropriately selected patients.

Emerging concepts in severe asthma management include the pursuit of asthma remission, defined as a sustained period of well-controlled asthma without exacerbations or the need for systemic corticosteroids, possibly even without biologics. While a challenging goal, current research is exploring predictors of remission on biologic therapy and developing criteria to define it. New biomarkers and combination therapies are also under investigation to further personalize treatment and achieve better long-term outcomes.

Ultimately, biologics represent a cornerstone of personalized medicine in severe asthma, moving beyond a one-size-fits-all approach to targeted treatment based on an individual's inflammatory phenotype. While they offer remarkable benefits, challenges remain, including identifying ideal responders, managing non-Type 2 severe asthma, and ensuring equitable access to these advanced therapies. Ongoing research continues to refine our understanding and expand the therapeutic arsenal for this complex disease.

References:
Gyawali B, Georas SN, Khurana S. Biologics in severe asthma: a state-of-the-art review. Eur Respir Rev 2025; 34: 240088.
Chung KF, Wenzel SE, Brozek JL, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J 2020;55:1900588.
Hanania NA, Wenzel S, Rosen K, et al. Exploring the effects of omalizumab in allergic asthma: an analysis of 3-year data from the EXTRA study. J Allergy Clin Immunol 2008;123:686-93.
Wenzel S, Castro M, Corren J, et al. Dupilumab efficacy and safety in patients with severe asthma and type 2 inflammation: a randomised, double-blind, placebo-controlled, phase 3 study. Lancet 2017;389:783-94.
Castro M, Wenzel SE, Holweg CTJ, et al. Reslizumab for inadequately controlled asthma with high eosinophil counts: results from two phase 3, randomised, double-blind, placebo-controlled trials. Lancet Respir Med 2015;3:347-56.